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PIH25
EnvElHEcImEnto PoPulacIonal E as PolítIcas PúblIcas DE saúDE no 
brasIl
Kernkamp Cd1, Massuda EM2
1Unicesumar - Centro Universitário de Maringá, MARINGÁ-PARANÁ, Brazil, 2Unicesumar - 
Centro Universitário de Maringá, Maringá-Paraná, Brazil
ObjetivOs: Caracterizar as políticas públicas de saúde no Brasil, com enfoque 
no envelhecimento populacional, na perspectiva histórica, econômica e constitu-
cional. MétOdOs: Revisão bibliográfica, retrospectiva, descritiva e comparativa de 
políticas públicas de saúde voltada aos idosos. A abordagem temporal se estende de 
1930 até a atualidade. ResultAdOs: O estudo evidenciou que as políticas públicas 
de saúde acompanham a trajetória econômica vigente do país, centradas temporal-
mente nos interesses econômicos: atividade agroexportadora (até 1930), processo 
de industrialização (1930-1990) e abertura econômica (1990-atual). Vinculam-se 
as políticas de saúde, sequencialmente, à erradicação das epidemias, principal-
mente, nas áreas portuárias, proteção do trabalhador urbano sob modelo excludente 
visando apenas aqueles inseridos no sistema formal de trabalho e, finalmente, 
a saúde como direito universal com a promulgação da Constituição Federal de 
1988. Nesse último período, estabeleceu-se o marco legal dos direitos dos idosos. A 
década de1990 e anos 2000 destacam-se pelas leis que amparam a pessoa idosa, tais 
como: a LOS – nº 8.080/1990, a LOAS / 1993; a Política Nacional da Assistência Social 
/2004; a Política Nacional do Idoso / 1994; o Estatuto do Idoso/2003; Pacto pela Vida 
/ 2006; a Política Nacional de Saúde da Pessoa Idosa/ 2006 e a resolução nomeada 
com Tipificação Nacional dos Serviços Socioassistenciais /2009. No período atual, 
o Brasil passa por processo de transição demográfica e epidemiológica devido ao 
aumento da expectativa de vida dos indivíduos; a redução do índice de natalidade 
e de mortalidade; a mudança do perfil demográfico e epidemiológico. Tais fatores 
contribuíram para o crescimento da demanda por serviços de saúde. COnClusões: 
Em período anterior a 1988 não se evidenciavam políticas públicas legais de proteção 
aos idosos. Observou-se que diversas ações de prevenção e promoção da saúde 
foram adotadas, principalmente em termos da legislação, após a Constituição de 
1988, visando garantir proteção social aos idosos.
PIH26
KnowlEDgE, attItuDE anD PractIcEs towarDs mEDIcatIon usE among 
Post-graDuatE PHarmacy stuDEnts
Hussain S1, Tiwari P2
1National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India, 
2National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), 
Punjab, India
ObjeCtives: To assess the knowledge and practice with respect to use of medi-
cines, among post-graduate pharmacy students. MethOds: This cross-sectional 
study was carried out among the post-graduate students of NIPER, Mohali, during 
the period of Nov. 2014 to Feb. 2015. The method of data collection was based on 
pre-designed questionnaire containing close ended questions. Participants were 
randomly selected. Questionnaire inquired about their knowledge with respect to 
medicine, attitude and practising behaviour. Reponses received during the study 
period were coded and analysed using SPSS. Results: A total of 200 students 
responded to the study. All the respondents were postgraduates in the age group 
of 20-30 years. About 95% respondents completed their dosage regimen as pre-
scribed. Almost all the respondents (86%) said that they always shake the cough 
syrup bottle before use. Almost a three-quarter respondents asked the prescriber 
or dispenser about the possible side-effects of the prescribed medication. Majority 
(94%) of the respondents practised self-medication. Most common reasons for 
practising self-medication was found to be convenience (37.5%) followed by quick 
relief (25%), time saving (15%), economical (8.5%) and others (14%). 71% of the 
respondents reported the habits of sharing medicine with others. High preva-
lence (91%), of unused medication was reported. Most common reason cited for 
unused medication was discontinuation of medicines when patients start feeling 
better. COnClusiOns: The result of this study reflects a high prevalence rate of 
self-medication and unused medication. This needs to be addressed appropri-
ately. Promotion of rational use of medicine is important to achieve the required 
effectiveness of the medicines.
mEntal HEaltH – clinical outcomes studies
PmH1
ImPact of nEgatIvE symPtoms on QualIty of lIfE In PatIEnts wItH 
scHIzoPHrEnIa
Novick D1, Montgomery W2, Cheng Y3, Moneta V4, Haro JM4
1Eli Lilly and Company, Surrey, UK, 2Eli Lilly Australia Pty Ltd., West Ryde, Australia, 3Lilly 
Suzhou Pharmaceutical Company, Ltd., Shanghai, China, 4Parc Sanitari Sant Joan de Déu, Sant Boi 
de Llobregat, Spain
ObjeCtives: The present study analyses the impact and influence of negative 
symptoms on quality of life (QoL). MethOds: The W-SOHO study is a three year 
follow-up study on the outpatient care of schizophrenia that included 17,384 
patients from 37 countries. Patients were recruited in W-SOHO by their treating 
psychiatrists when starting or changing antipsychotic medication. Evaluation 
was conducted during the normal course of care and was scheduled every six 
months after the baseline visit. The Clinical Global Impressions Severity Scale 
– Schizophrenia version (CGI-SCH) was used to assess symptom severity across 
overall, positive, negative, depressive and cognitive subdomains. Quality of life 
(QoL) was assessed using the EuroQOL 5-D questionnaire. Pearson correlation 
coefficients (PCC) were used to analyze the relationship between continuous vari-
ables. A mixed model with repeated measures (MMRM) was used to analyze the 
factors associated with quality of life during follow-up. Results: Quality of life at 
baseline was more highly correlated with negative symptoms than with positive 
InDIvIDual’s HEaltH – Health care use & Policy studies
PIH22
avalIação Da EfIcácIa E sEgurança Do IbuProfEno vErsus DEmaIs 
antI-Inflamat”rIos não EstEroIDaIs, no tratamEnto DE rEcém-
nascIDos PrEmaturos com PErsIstêncIa Do canal artErIal
Zanghelini F1, Andrade CA1, Leite BF2, Pitta MG1, Rego MJ1, Pereira MC1, Oliveira PS1, 
Oliveira MD1
1Universidade Federal de Pernambuco, Recife, Brazil, 2Ministério da Saúde, Brasília, Brazil
ObjetivOs: Avaliar a eficácia e segurança do ibuprofeno vs. demais anti-
inflamatórios não esteroidais, no tratamento de recém-nascidos prematuros com 
persistência do canal arterial. MétOdOs: Após elaborar a pergunta estruturada, 
a busca nas bases de dados MEDLINE, Cochrane Library, Tripdatabase, e CRD, foi 
realizada em 08/02/2015, utilizando os descritores MeSH (“Ductus Arteriosus, 
Patent”[Mesh]) AND (“Anti-Inflammatory Agents, Non-Steroidal”[Mesh]) AND 
(systematic[sb]) e seguiu as diretrizes de Avaliação de Tecnologias em Saúde 
do Ministério da Saúde. Foram identificadas 98 referências, após o processo de 
seleção norteado pela pergunta estruturada e pelos critérios de qualidade descri-
tos no instrumento AMSTAR, 6 referências relataram algum processo sistemático 
de recuperação de evidências. ResultAdOs: O risco relativo (RR) de alcançar o 
fechamento da persistência do canal arterial não apresentou diferença significativa 
entre o tratamento com ibuprofeno intravenos (IV)vs. indometacina (IV) (RR = 1; IC 
95% = 0.93–1.08). Quando comparado o ibuprofeno oral vs. indometacina oral ou 
IV, também não houve diferença estatisticamente significativa (RR = 0,96; IC 95% = 
0.73–1.27). Já quando comparado, ibuprofeno oral vs. (IV), o risco de falha no fecha-
mento da persistência do canal arterial foi 59% menor no grupo oral (RR = 0,41; IC 
95% = 0.27–0,64). Os resultados demonstram ainda uma menor tendência dos casos 
de enterocolite necrosante ao usar ibuprofeno oral. COnClusões: Ao comparar 
ibuprofeno (IV) vs. indometacina (IV), é necessário avaliar outros parâmetros para 
auxiliar na tomada de decisão. O ibuprofeno oral parece ser uma alternativa eficaz 
e segura, nos casos em que o intravenoso esta indisponível devido às diferentes 
restrições.
PIH23
gEnErIc Drugs aDoPtIon In turKIsH HEaltHcarE systEm
Atikeler K, Caliskan Z, Tuna E, Delibasi Barut M
Hacettepe University, Ankara, Turkey
ObjeCtives: Turkish Healthcare System under transformation since 2002 called 
“Health Transformation Programme’’. One of the key point regarding those changes 
is the introduction of “brand-generic drugs substitution”, in terms of the health 
and economic impact for the healthcare system. Primary concern is the mini-
mization of health expenses with satisfied health outcomes, for this countries 
need to eliminate unnecessary spending on medicines related prescribing and 
pricing within affordable limits for each stakeholder. The aims of this study are to 
show generic drug use of Turkey and marketshare of generics in pharmaceutical 
market of Turkey. We will focus on marketshares of generics and original drugs 
between the years 2008-2013 MethOds: Data of generic and original drugs sales 
percentage taken from Turkish Medical Devices and Medicines Agency report pub-
lished in 2014. Report data comprise of IMS data and indicated the years between 
2008-2013. Results: It has found that sales value of generic drugs increased 
from 33,5% to 36,2% from the years 2008 to 2013. In same period original drugs 
sales value decreased from 66,5% to 63,8%. In same period box sales of generics 
increased 24% while original drugs box sales increased %23. Despite of generic 
box sales increased 1% more than original box sales. It shown that price settings 
effects generic drugs more than original drugs during the period 2008-2013. On 
the other hand we can predict that drugs sales has close relation with drug price 
settings. Turkey is using internal and external reference pricing system since 
2004. COnClusiOns: Turkey has been processing “Health Transformation System’’ 
(HTP) since 2002. Drugs price settings was one of important key change is this 
programme. Drugs sales may affected from price setting. Drug usage increased 
as a result of HTP. Further studies needed to understand relationship between 
price settings and drug usage.
PIH24
cHaractErIstIcs of PEDIatrIc PatIEnts wItH rElaPsIng rEmIttIng 
multIPlE sclErosIs taKIng DIsEasE moDIfyIng agEnts
Greene N1, Greene M2
1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA
ObjeCtives: The objective of this study is to assess the characteristics of relapsing 
remitting multiple sclerosis (RRMS) patients taking disease modifying therapies 
(DMTs) in the US. MethOds: A large US administrative retrospective claims data-
base was used to identify patients diagnosed with RRMS and were prescribed DMTs 
between January 2010 to December 2012 were included in the study. All patients 
were ≤ 17 years of age and continuously enrolled in the same health plan for a year. 
Descriptive statistics and chi-square tests were performed on the data. Results: 
There were a total of 359 patients that met the study inclusion criteria. The mean 
age of the patients was 14.19 ± 2.29 years, 61.6% of the patients were females, and 
majority of the patients were between 12 and 17 years of age (85.5%). Thirty three 
percent of the patients were from East, 20.1% were from Midwest, 36.2% from South 
and 10.6% is from West region. 59.6% of the patients were on a group coverage plan 
and 49.3% of the patients were on a DMT prescription that is under their health 
plan formulary. Majority of the patients (95%) were prescribed 30 days’ supply of 
DMTs, 1.7% were on 60 days’ supply and 3.3% were on 90 days’ supply of DMTs. More 
than half of the patients (53.8%) were diagnosed with mental health problems in 
addition to their RRMS as a primary diagnosis. On average, patients were continu-
ously enrolled for 5.10 ± 1.74 years and submitting around 466 claims during this 
period. COnClusiOns: The majority of the pediatric patients were teenagers and 
females. One third of the patients was from south and received on average a 30 
days’ supply of DMT.
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was tolerability related to the number of withdrawals patients in each study, due 
to the presence of adverse events or treatment failure. The analyses were per-
formed using software Addis (v.1.16.5) and RevMan (5.1). Results: A total of 979 
documents were initially identified and 11 of them met the selection criteria to 
meta-analysis. No significant differences were observed between the number of 
withdrawals patients due adverse events in any meta-analysis of control ver-
sus intervention. The odds ratio ranged from 0.68 (CI 032-1.45) to placebo versus 
asenapine, 1.37 (CI 0.29-1.33) to placebo versus iloperidone and 0,71 (CI 0,36-1,41) 
to placebo versus lurasidone. However, all drugs were superior to their respective 
controls for the outcome of number of withdrawals by treatment failure, with 
odds ratio between 1.70 (CI 1.21-2.39) and 2.36 (CI 1.36-4.07). These results suggest 
that there is a higher effectiveness among patients for the treatment interven-
tion that should be evaluated through clinical responses. Heterogeneity between 
studies (evaluated by I2 values) were low or moderate, not superior than 39,5% 
in any meta-analysis. COnClusiOns: Information and knowledge reunion and 
confrontation on the tolerability profile of a particular drug allows safer decisions 
over the therapeutic approach, focused on patient’s interest which directly reflects 
on treatment follow-through and therapy effectiveness. In this study, we report 
evidence on asenapine, iloperidone and lurasidone greater tolerability profile 
compared to placebo in schizophrenia treatment.
mEntal HEaltH – cost studies
PmH5
lagrangE mEtHoD for buDgEt oPtImIzatIon analysIs In rEsourcE 
allocatIon for antIPsycHotIc tHEraPIEs In colombIa
Ariza JG1, Taborda A2, Cano JF3, Roa M2
1Janssen, Bogota, Colombia, 2Janssen Cilag, Bogota, Colombia, 3Grupo CISNE, Bogota, Colombia
ObjeCtives: To simulate the optimal budget allocation for first line antipsychotic 
medications in schizophrenia which minimize relapses. MethOds: From the 
health system perspective, a Lagrange budget optimization analysis was per-
formed with the SOLVER application in order to estimate the efficient market 
share of first line antipsychotics (oral, depot and Long Acting Injectable - LAI). 
The following parameters were gathered and validated in five psychiatric institu-
tions: target population, current market share, adherence to the treatment, risk 
of relapse, and the usage of outpatient and inpatient care resources. The tariffs 
were taken from official and institutional sources. The time frame was one year. 
Two scenarios were compared: the current and the optimum. Results: Current 
scenario: assuming a budget constraint of USD 250,000, a target population of 
381 patients and a baseline market share (oral 95.7%, depot 2.3% and LAI 2.0%), 
150 relapses were avoided (savings of USD 320,086). With the Optimum scenario 
market share [oral 83.0%, depot 4.0% and LAI 13.0%], 208 relapses were avoided 
[savings of USD 445,986]. COnClusiOns: Assuming a fixed budget for first line 
antipsychotic treatments, increasing the usage of LAI enable a budget optimiza-
tion and relapses minimization.
PmH6
costs of rElaPsE of scHIzoPHrEnIa for tHE argEntInIan HEaltH 
systEm
Peirano I1, Tellez D2, García C3, Malvestiti RA3, Pavan E4
1Janssen, Buenos Aires, Argentina, 2Janssen Cilag S.A., Bogotá, Colombia, 3Deloitte LATCO, Buenos 
Aires, Argentina, 4Deloitte Consulting, Buenos Aires, Argentina
ObjeCtives: To quantify the cost of schizophrenia relapse in Argentina from the 
perspective of the public and third party payer. Schizophrenia is a chronic, severe, 
and disabling mental disorder that significantly affects a person’s thought processes 
and emotional responsiveness. Due to the debilitating nature of the illness, people 
with schizophrenia have a relatively high utilization rate of health care and mental 
health services. Although there is currently no cure for schizophrenia, treatment 
is available to manage the symptoms and reduce the risk of relapse. However, poor 
adherence to treatment remains a significant issue with evidence showing that up 
to 60% of patients are partially or totally non-adherent to their prescribed oral treat-
ments. MethOds: A cost of disease study was performed including direct, indi-
rect and transference costs of relapses in schizophrenia. Bottom-up and top down 
methodologies were used to obtain direct costs of health care services consumed by 
this population. Validation of clinical criteria took place with local KOLs. Burden of 
disease was calculated using Disability Adjusted Life Years (DALY) supported by the 
CEPAL. The impact on the local economy was also included by obtaining transfer-
ence costs. Results: This study estimated that there were 415,870 patients with 
schizophrenia, from which 87.333 experienced some episode of relapse in Argentina. 
This corresponds to 21% of patients with schizophrenia. The total potential avoid-
able direct healthcare cost of relapse, total indirect cost over a 12 month period, and 
percentage of people not employed due to relapsing disease were calculated and 
will be presented in the publication. COnClusiOns: Argentinian decision makers 
in health can largely benefit by controlling relapses for these types of patients. 
This study is one of the first approaches at quantifying the impact of the disease 
and its relapse.
PmH7
costo DE EnfErmEDaDEs mEntalEs PrEvalEntEs En PErú
Mosqueira-Lovón R1, Gutierrez-Aguado A2, Escobedo-Palza S3, Timana-Ruiz R4, Sobrevilla-
Ricci A1
1Abt Associates-HFG Peru, Lima, Peru, 2UNMSM, Lima, Peru, 3SPEAS, Lima, Peru, 4SOMPEGS, 
Lima, Peru
ObjeCtivOs: Estimar los costos de enfermedades mentales prevalentes (EMP) 
en los establecimientos del Ministerio de Salud del Perú. MetOdOlOgíAs: Se 
realizó una evaluación económica parcial de tipo costo de enfermedad (CE). La 
población de estudio fue una cohorte hipotética de pacientes afiliada al Seguro 
Público de Salud (Seguro Integral de Salud) en el Perú. Los costos se estimaron 
symptoms (PCC -0.25 for positive symptoms and -0.29 for negative symptoms; 
p< 0.001). Improvement in negative symptoms was highly correlated to improve-
ment in QoL (PCC 0.33; p< 0.0001). The regression model analysing the influence 
of both positive and negative symptoms on QoL at baseline was confirmative and 
showed a greater beta coefficient (higher influence) for negative symptoms com-
pared with positive symptoms [(3.9 (se 0.14) versus 2.9 (se 0.13)]. Another model 
found that patients with greater negative symptoms at baseline experienced lower 
improvement in QoL (beta coefficient -0.81; se 0.11; p< 0.001). COnClusiOns: In 
patients with schizophrenia negative symptoms seem to have a larger influence 
onself-perceived QoL than positive symptoms. Improvement in negative symp-
toms is highly associated with improvements in QoL.
PmH2
avalIação DE tEcnologIas no tratamEnto Da DEPrEssão maIor: 
ovErvIEw sobrE a EfIcácIa E sEgurança Da DuloxEtIna, vEnlafaxIna E 
trazoDona comParaDos À fluoxEtIna
Marra LP1, Silva SN1, Costa Jd2, Acurcio FA1, Guerra-Júnior AA1
1College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2CCATES, Federal 
University of Minas Gerais, Belo Horizonte, Brazil
ObjetivOs: O objetivo desse estudo é revisar a evidência científica disponível sobre 
a eficácia e segurança dos antidepressivos de segunda geração duloxetina, venla-
faxina e trazodona em comparação à fluoxetina para o tratamento do Transtorno 
Depressivo Maior (TDM) em adultos. MétOdOs: Buscaram-se revisões sistemáticas 
(RS) de ensaios clínicos que comparassem a eficácia e segurança dos medicamentos 
duloxetina, venlafaxina e trazodona frente à fluoxetina para o tratamento do TDM nas 
bases de dados PUBMED, LILACS, CENTRAL e CRD. A avaliação da qualidade da evidên-
cia foi realizada por meio da ferramenta GRADE. Avaliações de Tecnologias de Saúde 
(ATS) e guias terapêuticos foram pesquisados em sites de agências nacionais e inter-
nacionais. O custo mensal do tratamento foi calculado para aquisições por compras 
públicas. ResultAdOs: Foram incluídas 12 RS com meta-análise. Em geral os estudos 
apresentaram baixa qualidade metodológica. Nove estudos apontaram superioridade 
do tratamento com venlafaxina frente à fluoxetina na redução de 50% dos sintomas. 
A razão de resposta (RR ou OR) entre os grupos venlafaxina e fluoxetina variou entre 
1,12 e 1,36. Em geral, a taxa de abandono e a incidência de eventos adversos foram 
maiores para os grupos venlafaxina e duloxetina, comparados ao grupo fluoxetina. As 
4 ATS encontradas concluíram que os antidepressivos de segunda geração possuíam 
eficácia comparável à da fluoxetina, com maior custo associado. O tratamento com a 
fluoxetina corresponde ao menor valor. COnClusões: Verificou-se baixa qualidade 
da evidência dos resultados, menor custo de tratamento com o medicamento fluox-
etina e recomendações das Agências de ATS e guias terapêuticos quanto a eficácia 
comparável entre os antidepressivos e indicação da fluoxetina no diagnóstico inicial 
do TDM. Recomenda-se que a fluoxetina seja o medicamento de primeira escolha 
para o tratamento do TDM em pacientes adultos e em caso de resposta inadequada, 
a venlafaxina poderia ser utilizada como segunda escolha.
PmH3
EvIDEncE of EffIcacy anD safEty of mEtHylPHEnIDatE In tHE 
trEatmEnt of cHIlDrEn or aDolEscEnts wItH attEntIon DEfIcIt 
DIsorDEr anD HyPEractIvIty (aDHD)
Leite BF1, Vidal JS2, Silva AS3, Brito GV1, Souza KM1, Freitas MG3, Vieira NC2, Wichmann R3, 
Silveira DS3
1Ministério da Saúde, Brasília, Brazil, 2Agência Nacional de Vigilância Sanitária, Brasília, Brazil, 
3Brazilian Ministry of Health, Brasília, Brazil
ObjeCtives: To evaluate the efficacy and safety of methylphenidate com-
pared to other pharmacological alternatives or placebo in the treatment of 
ADHD. MethOds: Health technology assessments (HTA), randomized clinical 
trials (RCT) or systematic reviews (SR) of RCT were systematically researched. 
Inclusion criteria were placebo or pharmacological intervention as comparators, 
and children or adolescents as population. Studies about different dosis or pres-
entations of methylphenidate were also selected. Results: One ECR, four SR and 
two HTA were selected comparing methylphenidate to placebo, atomoxetine, bus-
pirone, dexamphetamine. Methylphenidate was superior to placebo in the index of 
hyperactivity detected by parents and teachers, behavior during the execution of 
tasks, productivity in classroom and in precision of the activities. Response rates to 
treatment and abandonment were better as compared to atomoxetine. Compared 
to buspirone, methylphenidate was shown to be more effective in reducing the 
symptoms of ADHD. Benefits of methylphenidate on dexamphetamine are incon-
clusive. Low dose methylphenidate was superior to high dose in behavior improve-
ment on the execution of tasks. There was no difference between long and short 
acting presentations. Regarding security: anorexia, insomnia, migraines, stomach 
pain and dizziness were often associated with methylphenidate. COnClusiOns: 
Primary studies showed methodological limitations such as low quality, short fol-
low up and low capacity of generalization. The evaluation of the results should be 
cautious. It is necessary to find a balance between benefits and risks before start-
ing the administration of methylphenidate in children and adolescents, especially 
in long-term treatments.
PmH4
comParatIvE tolErabIlIty of nEw antIPsycHotIc Drugs In 
scHIzoPHrEnIa: a systEmatIc rEvIEw anD mEta-analysIs
Tonin FS, Piazza T, Wiens A, Pontarolo R
Universidade Federal do Paraná, Curitiba, Brazil
ObjeCtives: Evaluate the tolerability of three antipsychotic drugs – asenapine, 
iloperidone and lurasidone – in the treatment of schizophrenia. MethOds: An 
eletronic search was performed in Medline (Pubmed), Cochrane Library, Scopus, 
Science Direct and Scielo. A systematic review and meta-analysis of randomized 
controlled trials (RCTs) comparing the use of any of the above-mentioned drugs 
versusplacebo in schizophrenia was realized. Publications available in English, 
Portuguese, Spanish, French and German were evaluated. The main outcome 
